Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
DMAC
Strong SellDiaMedica Therapeutics Inc. · Healthcare · United States · $352M · Avg Vol: $939K/d
COMPANY DESCRIPTION
DiaMedica Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel recombinant proteins for the treatment of kidney disease and neurological disorders. The company's lead candidate, DM199, is a recombinant form of human kallikrein-1, which targets multiple pathways involved in organ damage and inflammation. DiaMedica's competitive position is centered on its proprietary therapeutic approach to conditions with significant unmet medical need.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | — |
| EPS | -0.26 | -0.60 | -0.60 | -0.70 | — | -0.72 | -0.81 | -0.81 | — |
| Shares | 53.9M | 38.0M | 42.8M | 53.7M | -0.3% | 53.9M | — | — | — |
| Debt | 0.5M | 0.4M | 0.3M | 0.2M | -20.0% | 0.2M | — | — | — |
| Equity | 31.8M | 51.1M | 40.7M | 56.1M | 20.8% | — | — | — | — |
| Op CF | -11.5M | -18.7M | -22.1M | -29.1M | — | -31.5M | — | — | — |
| Inv CF | 11.5M | -18.3M | 8.6M | -2.2M | — | — | — | — | — |
| Fin CF | -6.0K | 36.8M | 12.0M | 43.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of DMAC are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| DMAC | DiaMedica Therapeutics Inc.(you) | $352M | 17 | Strong Sell |
| IRD | Opus Genetics, Inc. | $335M | 15 | Strong Sell |
| STRO | Sutro Biopharma, Inc. | $340M | 15 | Strong Sell |
| OBIO | Orchestra BioMed Holdings, Inc. | $327M | 18 | Strong Sell |
| RNAC | Cartesian Therapeutics, Inc. | $304M | 17 | Strong Sell |
| ENTA | Enanta Pharmaceuticals, Inc. | $411M | 17 | Strong Sell |
| FHTX | Foghorn Therapeutics Inc. | $408M | 16 | Strong Sell |
| LRMR | Larimar Therapeutics, Inc. | $421M | 18 | Strong Sell |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $356M | 22 | Sell |
| VNDA | Vanda Pharmaceuticals Inc. | $322M | 20 | Sell |
Peer medians: ROE -25.6% · P/E 29.5x · Gross margin 58.8%